Car T Cell An Issue Of Hematology Oncology Clinics Of North America E Book

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton’s Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin’s Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin’s Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin’s lymphoma; and Targeting biology in non-Hodgkin’s lymphoma.

This issue of Hematology/Oncology Clinics will feature articles such as: Anaplastic large cell lymphomaj; New agents; Transplant, Uncommon variants; ATLL, CD30+ LPD of skin; NK/T, MF/SS; and many more!

In this issue of Hematology/Oncology Clinics, guest editors Drs. Sung-Yun Pai and Nirali N. Shah bring their considerable expertise to the topic of Gene-Based Therapies for Pediatric Blood Diseases. Top experts in the field cover key topics such as CAR T-cell therapy: current status; engineered T cells; NK-cell therapy; hemoglobinopathies: beta-thalassemia, sickle cell disease; hemophilia A/B; primary immunodeficiencies; and more. Contains 14 relevant, practice-oriented topics including the evolution of gene therapy; viral vectors in hematopoietic stem cell gene therapy; gene editing in hematopoietic stem cells; nonintegrating vectors and engineered capsids; regulatory aspects of gene therapy; and more. Provides in-depth clinical reviews on gene-based therapies for pediatric blood diseases, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, Guest Edited by F. Stephen Hodi, is devoted to Melanoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: State of Melanoma, Biology of Melanoma, Epidemiology of Melanoma, Surgical Management of Melanoma, Melanoma Adjuvant Therapy, Targeted Therapies for Melanoma, Non-cutaneous Melanomas, Immune Checkpoint Therapies for Melanoma, Resistance Mechanisms to Current Therapies, Cellular Therapy and Cytokine Treatments for Melanoma, Combinatorial Approaches to the Treatment of Melanoma, and Melanoma Future Directions.